Original Article
  

The Value of Anti-Drug Antibody Detection in Discriminating Patients from Healthy Controls and Predicting the Gross Motor Functional State in Patients with Pompe Disease

Abstract

Anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody formation is a major challenge in patients with Pompe disease receiving enzyme replacement therapy (ERT). The clinical significance of these antibodies and their detection methods remain uncertain. This study aimed to evaluate the diagnostic and functional relevance of anti-rhGAA antibodies in late-onset Pompe disease (LOPD) and to compare the performance of ELISA and Western blot assays.
Fourteen patients with LOPD undergoing ERT and 14 age- and sex-matched healthy controls were studied. Serum anti-rhGAA antibodies and their IgG, IgM, and IgA isotypes were quantified using ELISA and verified by Western blot. Motor function was assessed using the Pompe Motor Function Levels Questionnaire, an adapted version of the GMFCS validated for Pompe disease.
Total and isotype-specific anti-rhGAA antibody levels were significantly higher in patients than in controls. ROC analysis showed excellent discrimination between groups. Strong agreement was observed between ELISA and Western blot results. However, antibody levels were not significantly correlated with motor function grade. Given the small sample size (n = 14), this non-significant result may reflect limited statistical power rather than a true lack of association.
Anti-rhGAA antibody detection effectively distinguishes LOPD patients from healthy individuals. Western blot provides a reliable, low-cost alternative to ELISA, particularly useful in resource-limited settings. Nevertheless, the prognostic utility of antibody titers for functional outcomes remains uncertain and warrants larger, multicenter validation studies.

1. Hannah WB, Derks TGJ, Drumm ML, Grünert SC, Kishnani PS, Vissing J. Glycogen storage diseases. Nat Rev Dis Primers. 2023;9(1):46.
2. Stevens D, Milani-Nejad S, Mozaffar T. Pompe disease: a clinical, diagnostic, and therapeutic overview. Curr Treat Options Neurol. 2022;24(11):573-588.
3. Schoser B. Pompe disease: what are we missing? Ann Transl Med. 2019;7(13):292.
4. Labella B, Cotti Piccinelli S, Risi B, Caria F, Damioli S, Bertella E, et al. A comprehensive update on late-onset Pompe disease. Biomolecules. 2023;13(9):1279.
5. Gómez-Cebrián N, Gras-Colomer E, Poveda Andrés JL, Pineda-Lucena A, Puchades-Carrasco L. Omics-based approaches for the characterization of Pompe disease metabolic phenotypes. Biol (Basel). 2023;12(9):1159.
6. Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020;12(15):15856-15874.
7. Hahn A, Hennermann JB, Huemer M, Kampmann C, Marquardt T, Mengel E, et al. Diagnosis and care of infants and children with Pompe disease. Klin Padiatr. 2020.
8. Zhou Z, Austin GL, Shaffer R, Armstrong DD, Gentry MS. Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases. Trends Mol Med. 2019;25(12):1094-1109.
9. Molares-Vila A, Corbalán-Rivas A, Carnero-Gregorio M, González-Cespón JL, Rodríguez-Cerdeira C. Biomarkers in glycogen storage diseases: an update. Int J Mol Sci. 2021;22(9):4381.
10. Derks TGJ, Rodriguez-Buritica DF, Ahmad A, de Boer F, Couce ML, Grünert SC, et al. Glycogen storage disease type Ia: current management options, burden and unmet needs. Nutrients. 2021;13(11):3828.
11. Schoser B, Laforet P. Therapeutic thoroughfares for adults living with Pompe disease. Curr Opin Neurol. 2022;35(5):645-650.
12. Marques JS. The clinical management of Pompe disease: a pediatric perspective. Children (Basel). 2022;9(9):1404.
13. Angelini C. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease. Expert Rev Neurother. 2024;24(3):259-266.
14. Dalmia S, Sharma R, Ramaswami U, Hughes D, Jahnke N, Cole D, et al. Enzyme replacement therapy for late-onset Pompe disease. Cochrane Database Syst Rev. 2023;12(12):CD012993.
15. Ditters IAM, van Kooten HA, van der Beek NAME, van der Ploeg AT, Huidekoper HH, van den Hout JMP, et al. Are anti-rhGAA antibodies a determinant of treatment outcome in adults with late-onset Pompe disease? A systematic review. Biomolecules. 2023;13(9):1414.
16. Hubig L, Sussex AK, MacCulloch A, Hughes D, Graham R, Morris L, et al. Quality of life with late-onset Pompe disease: qualitative interviews and general public utility estimation in the United Kingdom. J Health Econ Outcomes Res. 2023;10(1):41-50.
17. Sarah B, Giovanna B, Emanuela K, Nadi N, Josè V, Alberto P, et al. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis. J Neurol. 2022;269(2):733-741.
18. Davison JE. Advances in diagnosis and management of Pompe disease. J Mother Child. 2020;24(2):3-8.
19. Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. 2019;7(13):291.
20. Desai AK, Li C, Rosenberg AS, Kishnani PS. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med. 2019;7(13):285.
21. Joanne M, Skye N, Tracy M. The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review. J Inherit Metab Dis. 2019;42(1):57-65.
22. Duong T, Kishnani PS, An Haack K, Foster MC, Gibson JB, Wilson C, et al. Motor responses in pediatric Pompe disease in the ADVANCE participant cohort. J Neuromuscul Dis. 2022;9(6):713-730.
23. Desai AK, Shrivastava G, Grant CL, Wang RY, Burt TD, Kishnani PS, et al. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titres: experience with bortezomib-based immunomodulation. Front Immunol. 2024;15:1360369.
24. Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M, Tsukimura T, et al. Structural and biochemical studies on Pompe disease and a “pseudodeficiency of acid alpha-glucosidase”. J Hum Genet. 2007;52(11):898-906.
25. Gragnaniello V, Pijnappel PWWM, Burlina AP, In ’t Groen SLM, Gueraldi D, Cazzorla C, et al. Newborn screening for Pompe disease in Italy: long-term results and future challenges. Mol Genet Metab Rep. 2022;33:100929.
26. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40-49.
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
Anti-rhGAA antibody ELISA Enzyme replacement therapy Motor function Pompe disease Western blot
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Aziz-Ahari S, Aminian M, Rahimian A, Nafissi S, Heidari M, Rabbani A, Zarnani A-H, Mohebbi A, Badv RS, salajegheh N, Mortezagholi S, Masoumi S, Hadipour Z, Boostani R, Beiraghi toosi M, Sayadpour Zanjani K, Khajeh A, Tonkaboni SH, Sadeghi M, Fatehi F, Vafaei E, Ashrafi MR. The Value of Anti-Drug Antibody Detection in Discriminating Patients from Healthy Controls and Predicting the Gross Motor Functional State in Patients with Pompe Disease. Iran J Allergy Asthma Immunol. 2025;:1-10.